Deal Announcement


DCS Advisory acts as exclusive financial advisor to Chiral Technologies, Inc. on its acquisition of Arbor Biosciences

02 Feb 2019

DCS Advisory, a leading investment banking firm, acted as exclusive financial advisor to Chiral Technologies, Inc., part of Daicel Corporation, on its acquisition of Arbor Biosciences.

Daicel is a global market leader in enantioselective chromatography. With the acquisition of Arbor Biosciences, Chiral and Daicel will gain business platforms in the genomics field and aim to provide broader solutions in the food, environment, and medical health care fields. 

*DCS Advisory is a legacy firm of DC Advisory US. Find out more >

Deal Team

Testimonials

“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth. When beginning the search for the right target to grow our business and increase our expertise in this critical and complex area, we knew we needed advisors who understood the complexities of our space as well as we did. The team at DCS Advisory provided us with excellent guidance throughout and orchestrated a seamless, efficient process.”

Joseph Barendt, Ph.D., President of Chiral Technologies, Inc.